Physicochemical convergence in antibody CDR3-VH repertoires recognizing phosphorothioate-modified oligonucleotides backbone - Scorecard - MDSpire

Physicochemical convergence in antibody CDR3-VH repertoires recognizing phosphorothioate-modified oligonucleotides backbone

  • By

  • Riccardo Galasso

  • Francesco Coppolino

  • Alessia Berbiglia

  • Grete Francesca Privitera

  • Agata Famà

  • Giuseppe Valerio De Gaetano

  • Germana Lentini

  • Concetta Beninati

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Convergence of Physicochemical Properties in CDR3-VH Antibody Repertoires Targeting Phosphorothioate-Modified Oligonucleotide Backbones

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationRevise to include direct source attribution.
Care Setting

Key Highlights

  • highlight_4

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients receiving PS-ASO therapies

          Development of high-affinity antibodies against PS-ASOs remains challenging

          Clinical Best Practices

          • practice_3

          Related Resources & Content

            Original Source(s)

            Physicochemical convergence in antibody CDR3-VH repertoires recognizing phosphorothioate-modified oligonucleotides backbone

            • by Riccardo Galasso, Francesco Coppolino, Alessia Berbiglia, Grete Francesca Privitera, Agata Famà, Giuseppe Valerio De Gaetano, Germana Lentini, Concetta Beninati

            • May 29, 2026

            Related Content

            Robotic Phlebotomy Trial: What the Patients Said

            Experts reflect on the future of phlebotomy in the light of new study results

            Could Genomics Improve Endometriosis Diagnosis?

            Integrated multi-omics study explores pathways tied to inflammation, hormones, and pain

            • May 25, 2026

            • 2 min
            A multidisciplinary RNA-guided approach to complement genomic analysis of unsolved patients with an inborn error of immunity